**Background**
Renal transplantation is a critical therapeutic intervention for patients with end-stage renal disease. However, the success of these transplants is often threatened by the recipient’s immune response, specifically the activation of T lymphocytes, which can lead to graft rejection. Interleukin-2 (IL-2) and its receptor play a pivotal role in the proliferation and activation of T cells, making the IL-2 receptor an ideal target for immunosuppressive therapy. By blocking the interaction between IL-2 and its receptor, it is possible to inhibit the immune response and prolong graft survival. In this context, we will introduce a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody – Basiliximab.
**Definition**
Basiliximab is a recombinant chimeric murine/human IgG1 monoclonal antibody that specifically targets the IL-2Rα (CD25) subunit. According to the Basiliximab description, this antibody acts as a potent inhibitor of T lymphocyte proliferation.
**In Vitro and In Vivo Studies**
The Basiliximab biological activity has been demonstrated through its high affinity for the IL-2 receptor. In vitro studies indicate that Basiliximab specifically inhibits T lymphocyte proliferation by binding to the IL-2Rα. Notably, it binds exclusively to activated lymphocytes and macrophages/monocytes, while resting T lymphocytes that do not express IL-2Rα remain unaffected. Binding assays using immobilized human IL-2R alpha/CD25 protein showed an EC50 value of 35.99 ng/mL. Furthermore, flow cytometry analysis of Romas cells labeling IL-2Ra/CD25 has confirmed its binding specificity.
Regarding Basiliximab In Vivo applications, research using a reduced uterine perfusion pressure (RUPP) rat model of placental ischemia has provided significant insights. In timed-pregnant Sprague Dawley (SD) rats, a single intravenous infusion of Basiliximab (0.07 mg/rat) resulted in a decrease in total placental natural killer cells. However, this treatment had no effect on lowering mean arterial pressure (MAP) or improving pup and placental weight. For researchers seeking detailed Basiliximab technical information, these results highlight the antibody’s ability to modulate specific immune cell populations in vivo. In conclusion, Basiliximab is a highly selective anti-IL-2Rα antibody that serves as a valuable tool for studying immunosuppression and renal transplantation.
Keywords
Basiliximab, 179045-86-4, CHI 621, CHI621, CHI-621, Interleukin Related, IL, renal transplantation, placental ischemia, preeclampsia, Inhibitor, inhibitor, inhibit
References
[1] McKeage K, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. BioDrugs. 2010 Feb 1;24(1):55-76.
[2] Cunningham M W, et al. The Role of Interleukin‐2 (IL‐2) in Natural Killer Cell (NK) Activation and Hypertension in a Preclinical Rat Model of Preeclampsia. The FASEB Journal, 2018, 32: 911.1-911.1.
[3] Chapman TM, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35.